photo
Speaker

Peter Berglund

CTO, HDT BIO
Seattle, Washington, United States
Dr. Berglund has over 25 years of experience in developing and evaluating novel vaccine technologies. As the original inventor of RNA vaccination he studied immune response, memory and protection against influenza and other viral infections. Previously, he was Executive Director of Research at Immune Design where he advanced products from discovery through Phase III clinical trials. Prior to that he led the vaccine division at Liquidia Technologies and vaccine discovery at AlphaVax. In those roles he has led teams of dozens and advanced more than a half-dozen products into clinical trials. Peter earned his PhD at the Karolinska Institute and thereafter conducted post-doctoral research at the Institute and at the Laboratory of Viral Disease at the National Institutes of Health.
Speaking In
4:15 PM - 5:15 PM (PDT)
Tuesday, June 14
Scientific breakthroughs during the pandemic are driving a lot of optimism around mRNA technology,…